



Review

## Research progress of vitiligo repigmentation: from oxidative stress to autoimmunity

Tingting Yu, Yan Wu, Zhenzhong Lu\*

Department of Dermatology, Wuzhong People's Hospital, Suzhou Wuzhong District Skin Disease Prevention and Treatment Institute, Suzhou Jiangsu 215128, China

### Article Info

### Abstract



#### Article history:

**Received:** November 12, 2023

**Accepted:** February 18, 2024

**Published:** April 30, 2024

Use your device to scan and read the article online



Vitiligo belongs to a frequent chronic autoimmune skin disease with the features of pigmented plaques on the diseased skin along with potential damage of melanocytes. There are many factors underlying the pathogenesis of vitiligo, among which oxidative stress is extensively regarded to be the critical factor leading to the loss of melanocytes. The changed redox state resulting from oxidative stress, containing ROS overproduction along with the reduced activity of the skin's antioxidant system, makes melanocytes less resistant to exogenous or endogenous stimuli, and ultimately pushes normal defense mechanisms, resulting in the loss of melanocytes. Given the crucial potential of innate together with adaptive immunity in vitiligo, there is growing evidence of a relation between oxidative stress and autoimmunity. Our review offers estimable insights into the possible properties of oxidative stress and autoimmunity in pathogenesis of vitiligo, as well as the potential role of antioxidant-based supportive therapy in vitiligo repigmentation, providing a hopeful value for further research and development of effective treatments.

**Keywords:** Autoimmune skin, Oxidative stress, Vitiligo repigmentation.

## 1. Introduction

As an autoimmune skin disease, vitiligo belongs to a relatively common acquired pigment disorder. It is featured by loss of skin pigment because of dysfunction of functional melanocytes, affecting about 1-2% of the global population. The main feature is obvious colorless pigment patches on the skin, reflecting the loss of epidermal melanocytes [1]. Lesions may appear locally or throughout the body and may aggregate to form large colorless areas. Due to the comparison between white areas and normal skin, vitiligo can have a profound impact on the quality of life of both children and adults, resulting in stigmatization, social isolation, and low self-esteem for those affected [2].

Many studies have shown that vitiligo is linked to insulin resistance, dyslipidemia along other metabolic disorders [3–5]. Various mechanisms targeting melanocyte destruction in vitiligo have been indicated, containing genetics, autoimmune response, oxidative stress, as well as the secretion of inflammatory mediators [6]. A variety of triggers, ranging from mechanical stimulation to chemical exposure, can be linked to the development of vitiligo, and these triggers are thought to trigger a stress response in keratinocytes as well as melanocytes, resulting in an imbalance between oxidative and antioxidant systems. Melanocytes together with keratinocytes affected by stress can

secret more pro-inflammatory cytokines as well as chemokines, forming an abnormal epidermal microenvironment, while damaged melanocytes release autoantigens along with immune stimulation signals [7]. In response to reactive oxygen species (ROS) overproduction, the main factor of peroxidative stress, the stimulated antigen release is sensed and processed through antigen-presenting cells (APCs) containing local dendritic cells (DCs), eventually leading to elevated infiltration of melanocyte-specific T cells as well as antibodies against melanocytes' production around and in the vitiligo skin, activating an adaptive immune response in the vitiligo epidermis [8], leading to melanocyte dysfunction and death.

The therapy of vitiligo is not easy, it is on the basis of the spread along with location of the damage, and whether the condition is stable. In addition to traditional phototherapy, and local or systemic steroid therapy, years of research into etiology have resulted in the development of targeted treatments that are more efficient and have fewer side influences. The objective of this paper was to analyze the interaction between oxidative stress and autoimmunity underlying the pathogenesis of vitiligo through a narrative review of the literature, in order to provide insights on the

\* Corresponding author.

E-mail address: [enigmaago@126.com](mailto:enigmaago@126.com) (Z. Lu).

Doi: <http://dx.doi.org/10.14715/cmb/2024.70.4.23>

treatment of vitiligo repigmentation from the blocking of oxidative stress and autoimmune-related pathways.

## 2. Oxidative stress in vitiligo

Although numerous theories have been proposed regarding the cause of vitiligo, there is no consensus on the accurate cause of how melanocytes are damaged and finally die. Oxidative stress has a crucial potential in the pathogenesis of vitiligo, resulting in the injury of melanocytes [9]. Oxidative stress induces a redox homeostatic imbalance, presented by overproduction along with inadequate clearance of ROS. ROS can be induced by both endogenous together with exogenous stimuli, ultimately resulting in the death of melanocytes. In the process of melanin production, excessive ROS production forms an oxygenophilic environment, making melanocytes vulnerable to oxidative stress [10].

Melanocytes have been reported to suffer cumulative damage from ROS, which disrupts the structure and function of their DNA, lipids, as well as proteins [11]. Oxidative stress can result in vitiligo via a variety of mechanisms. For example, oxidative stress leads to decreased expression of GATA3 and affects SIRT3-mediated deacetylation of HMGB1, thus significantly inhibiting melanin secretion and expression of melanin-related proteins, leading to increased apoptosis [12]. In addition, results from another study show that SIRT3 expression and activity are significantly reduced in vitiligo melanocytes. Loss of SIRT3 induces mitochondrial dysfunction as well as the release of cytochrome C, leading to more apoptosis of melanocytes [13]. Zhou *et al.* [14] reported that the transitional accumulation of ROS destroyed the melanin synthesis process as well as caused the destruction of lipid stability in melanocytes, leading to the damage of the mitochondrial electron transport chain as well as the sharp increase of ROS production, resulting in a vicious cycle, resulting in a large number of melanocytes dying [14]. Many studies have confirmed that the increase of ROS belongs to a key factor in promoting the secretion of chemokines by keratinocytes, which guide CD8<sup>+</sup> T cells and result in migration to skin tissues, resulting in melanocyte death [15]. For example, the decreased expression of AQP3 in keratinocytes of vitiligo patients leads to increased oxidative stress of neighboring melanocytes, resulting in the death of melanocytes [16].

## 3. Role of ROS and immune system in vitiligo

It has been reported that oxidative stress as well as autoimmunity with genetic susceptibility are related to the pathogenesis of vitiligo [17]. Exogenous or endogenous stimuli cause melanocytes to stress and produce excessive ROS, which contributes to the secretion of damage-associated molecular patterns (DAMPs) as well as the secretion of melanosomal antigens that stimulate innate immunity.

### 3.1. Innate immunity

Reactive oxygen species regulate various immune together with inflammatory molecules. Followed by sensing oxidative stress signals, the innate immune system responds quickly to these signals. Innate immunity then converts stress signals into pro-inflammatory signals, providing a rapid response for better protection. Toll-like receptors and nucleotide oligomeric domain (NOD)-like receptors can be involved in pro-inflammatory signaling.

Autoantigens are secreted by the body's cells, not by pathogen-linked molecules. They produce pro-inflammatory signals to promote an immune response.

Unfolded proteins form as well as accumulate when oxidative stress disturbs the redox potential. The unfolded protein response (UPR) is the steady-state recovery of cells against unfolded proteins together with inappropriate protein folding caused by ER dysfunction. UPR belongs to an initial pro-survival signaling in which translation is weakened and the cell cycle is stopped to hinder further translation loading of the ER [18].

Activated UPR consists of 3 major endoplasmic reticulum transmembrane receptors: eukaryotic initiation factor 2 $\alpha$  kinase (PERK), activating transcription factor 6 (ATF6) along with inositol requiring 1 (IRE1 $\alpha$ ) [19, 20]. Chen *et al.* [21] reported that amino acid metabolite homocysteine up-regulates PERK expression by activating ROS, thus activating PERK-eIF2 $\alpha$ -CHOP pathway to induce apoptosis of vitiligo melanocytes [21].

Another cytoprotective agent involved in progressive pigmentation loss is the 70-kDa heat shock protein (Hsp70). In response to stress, Hsp70 serves to be a chaperone, binding to melanocyte-specific melanosome proteins, promoting protein folding and transport, and major histocompatibility complex I/II load [22]. For instance, studies have displayed that HSP70 mRNA expression is significantly enhanced in diseased skin biopsies of vitiligo patients than in non-focal skin biopsies of vitiligo patients [23]. In addition, LBP can protect keratinocytes from oxidative stress through CXCL9/CXCL10 pathway by down-regulating the expression of Hsp70 [24].

Additionally, exosomes also have a crucial role in the innate immunity of vitiligo. These exosomes create an inflammatory microenvironment, causing inflammation along with recruiting immune cells to clear stressed melanocytes. In their study, Zhang *et al.* [25] reported that the patient-derived exosome miR-21-5p inhibited melanin production in melanocytes by targeting SATB1 in vitiligo. In addition, the downregulation of keratinocyte-derived exosome miR-200c inhibits melanin production in vitiligo lesions [26].

### 3.2. Adaptive immunity

The concept that innate immunity can mediate the presentation of autoantigens to induce autoimmunity fills the gap between oxidative stress and adaptive immunity [17]. Studies have shown that melanocyte-specific CD8<sup>+</sup> T cells mediate the damage of melanocytes in vitiligo [27]. Antigen proteins from stress melanocytes are carried by DC and are specifically identified by infiltrated T cells. At the front of vitiligo decolorization, T cells appear patchy infiltration. The frequency of serum CD8<sup>+</sup> T cells in vitiligo patients presents higher relative to healthy controls and the frequency is correlated with disease severity. CD8<sup>+</sup> T cells secrete several cytokines, containing TNF- $\alpha$  as well as IFN- $\gamma$ , which are mainly implicated in the damage of melanocytes. After IFN- $\gamma$  pro-inflammatory cytokines bind to their receptors, the Janus kinase signal transduction and transcriptional activator pathway can be stimulated and promotes the transcription of the chemokine ligands CXCL9 along with CXCL10 [28]. Clinically, serum CXCL10 represents a specific biomarker for monitoring the activity and severity of vitiligo [29]. CXCL9/10 modulates recruitment of melanocyte-specific CD8<sup>+</sup> T cell

migration via binding to CXCR3.

#### 4. Vitiligo repigmentation

Current therapies for vitiligo repigmentation contain phototherapy, local and systemic immunosuppressants, as well as surgery, which require long-time follow-up to evaluate the effectiveness of treatment. However, with these non-targeted treatment options, there are no effective therapies that can stimulate complete repigmentation, so more therapeutic approaches are needed to treat vitiligo.

##### 4.1. Antioxidant therapy for vitiligo

Antioxidants are compounds that can greatly reduce or block the detrimental impacts of free radicals on human tissues [30]. Antioxidant-based supportive treatments have been proposed as therapies to prevent skin aging [31], skin cancer [32], and skin autoimmune diseases [33]. To date, many drugs including antioxidant-like substances have been studied to support or replace standard therapies for vitiligo.

Vitamin C reduces oxidative stress through oxidizing ascorbic acid to monodehydroascorbic acid and dehydroascorbic acid. Vitamin C together with its derivatives suppresses tyrosinase activity along with melanin content through a dose-dependent way [34]. The results of a randomized controlled trial showed that oral vitamin C reduced the serum stress oxidation index in patients with vitiligo [35]. However, another systematic review and meta-analysis of vitamin C failed to show reproducible results [36].

Vitamin E belongs to a photoprotective antioxidant absorbing certain wavelengths along with preventing lipid peroxidation [37]. Vitamin E can prevent oxidative stress caused by UV-A phototherapy, but does not affect the clinical improvement of vitiligo lesions [38]. Nevertheless, the combination of narrow-spectrum UVB and oral vitamin E may improve the therapeutic effect [39].

Selenium is identified to be a crucial trace element regulating oxidative stress [40]. A meta-analysis by Dai *et al.* [40] revealed reduced selenium levels in Asian vitiligo patients, while this finding was not observed in Caucasian patients. Zinc can protect melanocytes via its anti-apoptotic as well as antioxidant roles. It can also modulate melanin production via releasing alpha-melanocyte stimulants and precipitation of zinc- $\alpha$ 2-glycoproteins in tissues. Also, zinc belongs to a kind of non-specific elements that help regulate cell-mediated immunity as well as control gene expression [41]. One study evaluated changes in serum zinc levels in a group of Iranian patients with vitiligo. The results suggested that disturbances in serum zinc levels were associated with vitiligo and may have a crucial potential in the development of the disease in Iranian patients [42]. The main role of copper is that it promotes the production of melanin and participates in destroying free radicals by forming superoxide dismutase, thus providing physiological protection against oxidative stress [43].

*Ginkgo biloba* is a traditional Chinese herb. *G. biloba* extract prevents apoptosis induced by oxidative damage of melanocytes through repressing  $H_2O_2$  and inhibits the autoimmune response of melanocytes through repressing the secretion of Hsp70 [44]. Studies have demonstrated the efficacy of oral administration of *G. biloba* in the treatment of localized, slow-spreading vitiligo [45]. In addition, *G. biloba* extract EGb761 prevents human melanocytes from  $H_2O_2$ -stimulated oxidative stress via inducing Nrf2 [46].

Coenzyme Q10 belongs to a universal vitamin-like compound that acts as an electron transporter in the mitochondrial respiratory chain, which has a crucial potential in the metabolism of fatty acids, pyrimidines, as well as lysosomes, and modulates some genes' expression, containing those implicated in inflammation [47]. In a randomized trial conducted in Iraq, researchers discovered an apparent decrease in the vitiligo regional score index followed by 8 weeks of topical use of CoQ10 gel [48].  $\alpha$ -lipoic acid reacts with ROS together with active nitrogen in the form of reduced dihydrolipoate and protects cell membranes via disturbing vitamin C and E pathways [49]. A randomized clinical trial demonstrated no significant benefit of oral alpha-lipoic acid and UV-A phototherapy in the treatment of vitiligo [50]. However, another clinical study demonstrated that the combination of oral alpha-lipoic acid, beta-methasone injection and UV-A phototherapy is effective and safe for non-segmentary progressive vitiligo [51].

Emblica possesses a high antioxidant ability because of its high purity of polyphenol compounds together with vitamin C. Fruit extracts are adopted as antioxidants, which repress lipid peroxidation as well as remove free radicals containing superoxide anion, hydrogen free radical, hydrogen peroxide, as well as nitric oxide free radical [52]. In a clinical study, an oral supplement of emblica fruit extract can effectively improve vitiligo [53].

##### 4.2. Immunotherapy for vitiligo

As part of vitiligo management, there is an urgent need to stop abnormal innate immunity, and unfortunately, there are few new strategies to achieve this. Mosenson *et al.* [54] found that the application of HSP70iQ435A coding DNA several months previous to spontaneous pigmentation loss hindered vitiligo in mice expressing the transgenic melanocyte reactive T cell receptor. They successfully offset depigmentation in mice with spontaneous vitiligo. In 2018, Henning *et al.* [55] obtained similar results in pigs. As for drug treatment, topical application of vitamin D has been documented to decrease the number of DC in vitiligo skin [56].

Immunosuppressive therapy has always been the mainstream of vitiligo therapy, and the far-reaching effects of immune abnormalities on the destruction of melanocytes are also echoed. Currently, recommended immunosuppressive interventions contain topical steroids, calcineurin inhibitors (tacrolimus and pimecicimus), along with oral impact steroids. However, the above interventions are only moderately effective.

As previously documented, the IFN- $\gamma$ -CXCL9/CXCL10-CXCR3 signaling is integral in CD8<sup>+</sup> T cell killing of melanocytes, and disruption of this axis is effective in preventing vitiligo progression and promoting hyperpigmentation [57]. Richmond *et al.* [58] successfully cleared TRM from vitiligo-affected skin by long-term administration of anti-CD122 antibodies. CD122 belongs to a subunit of the heterotrimer IL-15 receptor, so blocking CD122 may repress TRM residency in the skin via eliminating IL-15 support [58].

#### 5. Conclusion and prospect

Oxidative stress as well as autoimmunity is the main theories of vitiligo. But without convergence, we cannot comprehend these two mechanisms of disease. In fact, novel insights into how these two pathways work together

may help to better understand the pathogenesis underlying vitiligo. In summary, this study reviewed the potential of oxidative stress and autoimmunity in vitiligo. First, both exogenous and endogenous stimuli enhance melanocyte stress, resulting in an excess of ROS, which promotes the production of DAMPs along with the release of melanosomal antigens that stimulate innate immunity. In addition, this study reviewed the latest progress in treating vitiligo from the viewpoint of inhibiting oxidative stress as well as autoimmunity. However, the role of oxidative stress as well as autoimmunity in vitiligo needs to be better understood to develop more promising treatments.

### Informed consent

The authors report no conflict of interest.

### Availability of data and material

We declared that we embedded all data in the manuscript.

### Authors' contributions

YT conducted the experiments and wrote the paper; WY analyzed and organized the data; LZ conceived, designed the study and revised the manuscript.

### Funding

None.

### Acknowledgements

We thanked Wuzhong People's Hospital, Suzhou Wuzhong District Skin Disease Prevention and Treatment Institute approval our study.

### References

- Ezzedine K, Eleftheriadou V, Whitton M, van Geel N (2015) Vitiligo. *Lancet* 386(9988):74–84. doi: 10.1016/s0140-6736(14)60763-7
- Radi G, Simonetti O, Diotallevi F, Campanati A, Brisigotti V, Molinelli E, Offidani A (2020) How can I take care of you? The dermatologist meets patients' needs during the COVID-19 pandemic. *Dermatol Ther* 33(4):e13740. doi: 10.1111/dth.13740
- Aryanian Z, Shirzadian A, Farzaneh S, Goodarzi A, Azizpour A, Hatami P (2022) Metabolic derangement in patients with vitiligo: a cross-sectional study. *J Investig Med* 70(4):963–966. doi: 10.1136/jim-2021-002062
- Kang P, Zhang WG, Ji ZH, Shao ZJ, Li CY (2022) Association between vitiligo and relevant components of metabolic syndrome: a systematic review and meta-analysis. *J Dtsch Dermatol Ges* 20(5):629–641. doi: 10.1111/ddg.14717
- Chuang KW, Chang HC (2022) Association between vitiligo and metabolic syndrome: A systematic review and meta-analysis. *J Dtsch Dermatol Ges* 20(2):218–221. doi: 10.1111/ddg.14652
- Bergqvist C, Ezzedine K (2020) Vitiligo: A Review. *Dermatology* 236(6):571–592. doi: 10.1159/000506103
- Xie H, Zhou F, Liu L, Zhu G, Li Q, Li C, Gao T (2016) Vitiligo: How do oxidative stress-induced autoantigens trigger autoimmunity? *J Dermatol Sci* 81(1):3–9. doi: 10.1016/j.jdermsci.2015.09.003
- El-Gayyar MA, Helmy ME, Amer ER, Elsaied MA, Gaballah MA (2020) Antimelanocyte antibodies: a possible role in patients with vitiligo. *Indian J Dermatol* 65(1):33–37. doi: 10.4103/ijid.IJD\_344\_18
- Mulayim MK, Kurutas EB, Nazik H, Ozturk P (2022) Assessment of oxidative/nitrosative stress and raftlin in vitiligo. *Indian J Dermatol* 67(5):624. doi: 10.4103/ijid.ijd\_917\_20
- Chang WL, Ko CH (2023) The role of oxidative stress in vitiligo: an update on its pathogenesis and therapeutic implications. *Cells* 12(6):936. doi: 10.3390/cells12060936
- Mitra S, De Sarkar S, Pradhan A, Pati AK, Pradhan R, Mondal D, et al (2017) Levels of oxidative damage and proinflammatory cytokines are enhanced in patients with active vitiligo. *Free Radic Res* 51(11-12):986–994. doi: 10.1080/10715762.2017.1402303
- Nie XJ, Hao BZ, Zhang BL, Li YY (2023) GATA3 ameliorates melanocyte injuries in vitiligo through SIRT3-mediated HMGB1 deacetylation. *J Dermatol* 50(4):472–484. doi: 10.1111/1346-8138.16634
- Yi X, Guo W, Shi Q, Yang Y, Zhang W, Chen X, et al (2019) SIRT3-dependent mitochondrial dynamics remodeling contributes to oxidative stress-induced melanocyte degeneration in vitiligo. *Theranostics* 9(6):1614–1633. doi: 10.7150/thno.30398
- Zhou J, An X, Dong J, Wang Y, Zhong H, Duan L, et al (2018) IL-17 induces cellular stress microenvironment of melanocytes to promote autophagic cell apoptosis in vitiligo. *Faseb j* 32(9):4899–4916. doi: 10.1096/fj.201701242RR
- He S, Xu J, Wu J (2022) The promising role of chemokines in vitiligo: from oxidative stress to the autoimmune response. *Oxid Med Cell Longev* 2022:8796735. doi: 10.1155/2022/8796735
- Kim NH, Kim HJ, Lee AY (2023) Aquaporin-3 downregulation in vitiligo keratinocytes increases oxidative stress of melanocytes. *Biomol Ther (Seoul)* 31(6):648–654. doi: 10.4062/biomolther.2023.112
- Wang Y, Li S, Li C (2019) Perspectives of new advances in the pathogenesis of vitiligo: from oxidative stress to autoimmunity. *Med Sci Monit* 25:1017–1023. doi: 10.12659/msm.914898
- Wiseman RL, Mesgarzadeh JS, Hendershot LM (2022) Reshaping endoplasmic reticulum quality control through the unfolded protein response. *Mol Cell* 82(8):1477–1491. doi: 10.1016/j.molcel.2022.03.025
- Jadeja SD, Mayatra JM, Vaishnav J, Shukla N, Begum R (2020) A concise review on the role of endoplasmic reticulum stress in the development of autoimmunity in vitiligo pathogenesis. *Front Immunol* 11:624566. doi: 10.3389/fimmu.2020.624566
- Read A, Schröder M (2021) The unfolded protein response: an overview. *Biology (Basel)* 10(5):384. doi: 10.3390/biology10050384
- Chen J, Zhuang T, Chen J, Tian Y, Yi X, Ni Q, et al (2020) Homocysteine induces melanocytes apoptosis via PERK-eIF2 $\alpha$ -CHOP pathway in vitiligo. *Clin Sci (Lond)* 134(10):1127–1141. doi: 10.1042/CS20200218
- Mosenson JA, Flood K, Klarquist J, Eby JM, Koshoffer A, Boissy RE, et al (2014) Preferential secretion of inducible HSP70 by vitiligo melanocytes under stress. *Pigment Cell Melanoma Res* 27(2):209–220. doi: 10.1111/pcmr.12208
- Doss RW, El-Rifaie AA, Abdel-Wahab AM, Gohary YM, Rashed LA (2016) Heat shock protein-70 expression in vitiligo and its relation to the disease activity. *Indian J Dermatol* 61(4):408–412. doi: 10.4103/0019-5154.185704
- Peng L, Lu Y, Gu Y, Liang B, Li Y, Li H, et al (2023) Mechanisms of action of *Lycium barbarum* polysaccharide in protecting against vitiligo mice through modulation of the STAT3-Hsp70-CXCL9/CXCL10 pathway. *Pharm Biol* 61(1):281–287. doi: 10.1080/13880209.2022.2163406
- Zhang C, Guo W, Wang S, Di Y, Wu D (2022) Peripheral blood of vitiligo patients-derived exosomal miR-21-5p inhibits melanocytes melanogenesis via targeting SATB1. *Iran J Public Health* 51(12):2706–2716. doi: 10.18502/ijph.v51i12.11461
- Zhao C, Wang D, Wang X, Mao Y, Xu Z, Sun Y, et al (2020) Down-regulation of exosomal miR-200c derived from keratino-

- cytes in vitiligo lesions suppresses melanogenesis. *J Cell Mol Med* 24(20):12164–12175. doi: 10.1111/jcmm.15864
27. van den Boorn JG, Konijnenberg D, DelleMijn TA, van der Veen JP, Bos JD, Melief CJ, et al (2009) Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. *J Invest Dermatol* 129(9):2220–2232. doi: 10.1038/jid.2009.32
28. Chang WL, Lee WR, Kuo YC, Huang YH (2021) Vitiligo: an autoimmune skin disease and its immunomodulatory therapeutic intervention. *Front Cell Dev Biol* 9:797026. doi: 10.3389/fcell.2021.797026
29. Abdallah M, El-Mofty M, Anbar T, Rasheed H, Esmat S, Al-Tawdy A, et al (2018) CXCL-10 and interleukin-6 are reliable serum markers for vitiligo activity: a multicenter cross-sectional study. *Pigment Cell Melanoma Res* 31(2):330–336. doi: 10.1111/pcmr.12667
30. Michalak M (2022) Plant-derived antioxidants: significance in skin health and the ageing process. *Int J Mol Sci* 23(2):585. doi: 10.3390/ijms23020585
31. Masaki H (2010) Role of antioxidants in the skin: anti-aging effects. *J Dermatol Sci* 58(2):85–90. doi: 10.1016/j.jdermsci.2010.03.003
32. Sable KA, Shields BE (2023) The role of dietary antioxidants in melanoma and nonmelanoma skin cancer. *Cutis* 111(1):33–48. doi: 10.12788/cutis.0672
33. Guarneri F, Bertino L, Pioggia G, Casciaro M, Gangemi S (2021) Therapies with antioxidant potential in psoriasis, vitiligo, and lichen planus. *Antioxidants (Basel)* 10(7):1087. doi: 10.3390/antiox10071087
34. Xing X, Dan Y, Xu Z, Xiang L (2022) Implications of oxidative stress in the pathogenesis and treatment of hyperpigmentation disorders. *Oxid Med Cell Longev* 2022:7881717. doi: 10.1155/2022/7881717
35. Fallah M, Abedini R, Mahiabadi SA, Montazeri S, Hosseinzadeh-Attar MJ, Ebrahimpour-Koujan S (2023) The effect of vitamin C on oxidative stress indices and skin repigmentation of vitiligo patients. *Arch Dermatol Res* 315(9):2655–2660. doi: 10.1007/s00403-023-02687-2
36. Speeckaert R, Dugardin J, Lambert J, Lapeere H, Verhaeghe E, Speeckaert MM, van Geel N (2018) Critical appraisal of the oxidative stress pathway in vitiligo: a systematic review and meta-analysis. *J Eur Acad Dermatol Venereol* 32(7):1089–1098. doi: 10.1111/jdv.14792
37. Sardana K, Sachdeva S (2022) Role of nutritional supplements in selected dermatological disorders: a review. *J Cosmet Dermatol* 21(1):85–98. doi: 10.1111/jocd.14436
38. Akyol M, Celik VK, Ozcelik S, Polat M, Marufihah M, Atalay A (2002) The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. *Eur J Dermatol* 12(1):24–26.
39. Dell'Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, et al (2007) Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. *Clin Exp Dermatol* 32(6):631–636. doi: 10.1111/j.1365-2230.2007.02514.x
40. Dai T, Xiaoying S, Li X, Hongjin L, Yaqiong Z, Bo L (2020) Selenium level in patients with vitiligo: a meta-analysis. *Biomed Res Int* 2020:7580939. doi: 10.1155/2020/7580939
41. Sanad EM, El-Fallah AA, Al-Doori AR, Salem RM (2020) Serum zinc and inflammatory cytokines in vitiligo. *J Clin Aesthet Dermatol* 13(12 Suppl 1):S29–S33. doi:
42. Khoshdel Z, Gholijani N, Niknam M, Rahmani N, Hemmati-Dinarvand M, Naghibalhossaini F (2022) Serum copper and zinc levels among iranian vitiligo patients. *Dermatol Pract Concept* 12(4):e2022140. doi: 10.5826/dpc.1204a140
43. Wacewicz M, Socha K, Soroczyńska J, Niczyporuk M, Aleksiejczuk P, Ostrowska J, Borawska MH (2018) Selenium, zinc, copper, Cu/Zn ratio and total antioxidant status in the serum of vitiligo patients treated by narrow-band ultraviolet-B phototherapy. *J Dermatolog Treat* 29(2):190–195. doi: 10.1080/09546634.2017.1357797
44. Lu L, Wang S, Fu L, Liu D, Zhu Y, Xu A (2016) Bilobalide protection of normal human melanocytes from hydrogen peroxide-induced oxidative damage via promotion of antioxidant expression and inhibition of endoplasmic reticulum stress. *Clin Exp Dermatol* 41(1):64–73. doi: 10.1111/ced.12664
45. Parsad D, Pandhi R, Juneja A (2003) Effectiveness of oral *Ginkgo biloba* in treating limited, slowly spreading vitiligo. *Clin Exp Dermatol* 28(3):285–287. doi: 10.1046/j.1365-2230.2003.01207.x
46. Zhang S, Yi X, Su X, Jian Z, Cui T, Guo S, et al (2019) *Ginkgo biloba* extract protects human melanocytes from from H<sub>2</sub>O<sub>2</sub>-induced oxidative stress by activating Nrf2. *J Cell Mol Med* 23(8):5193–5199. doi: 10.1111/jcmm.14393
47. Hargreaves I, Heaton RA, Mantle D (2020) Disorders of human coenzyme Q10 metabolism: an overview. *Int J Mol Sci* 21(18). doi: 10.3390/ijms21186695
48. Białyzyk A, Welniak A, Kamińska B, Czajkowski R (2023) Oxidative stress and potential antioxidant therapies in vitiligo: a narrative review. *Mol Diagn Ther* 27(6):723–739. doi: 10.1007/s40291-023-00672-z
49. Shakhbazova A, Wu H, Chambers CJ, Sivamani RK (2021) A systematic review of nutrition, supplement, and herbal-Based adjunctive therapies for vitiligo. *J Altern Complement Med* 27(4):294–311. doi: 10.1089/acm.2020.0292
50. Sun Y, Guan X, Wang H, Zhang J, Gu H, Lu H, et al (2021) Randomized clinical trial of combined therapy with oral  $\alpha$ -lipoic acid and NB-UVB for nonsegmental stable vitiligo. *Dermatol Ther* 34(1):e14610. doi: 10.1111/dth.14610
51. Li L, Li L, Wu Y, Gao XH, Chen HD (2016) Triple-combination treatment with oral  $\alpha$ -lipoic acid, betamethasone injection, and NB-UVB for non-segmental progressive vitiligo. *J Cosmet Laser Ther* 18(3):182–185. doi: 10.3109/14764172.2015.1114646
52. Di Nardo V, Barygina V, França K, Tirant M, Valle Y, Lotti T (2019) Functional nutrition as integrated approach in vitiligo management. *Dermatol Ther* 32(4):e12625. doi: 10.1111/dth.12625
53. Colucci R, Dragoni F, Conti R, Pisaneschi L, Lazzeri L, Moretti S (2015) Evaluation of an oral supplement containing *Phyllanthus emblica* fruit extracts, vitamin E, and carotenoids in vitiligo treatment. *Dermatol Ther* 28(1):17–21. doi: 10.1111/dth.12172
54. Mosenson JA, Zloza A, Nieland JD, Garrett-Mayer E, Eby JM, Huelsmann EJ, et al (2013) Mutant HSP70 reverses autoimmune depigmentation in vitiligo. *Sci Transl Med* 5(174):174ra128. doi: 10.1126/scitranslmed.3005127
55. Henning SW, Fernandez MF, Mahon JP, Duff R, Azarafrooz F, Guevara-Patiño JA, et al (2018) HSP70i(Q435A)-encoding DNA repigments vitiligo lesions in sinclair swine. *J Invest Dermatol* 138(12):2531–2539. doi: 10.1016/j.jid.2018.06.186
56. Gorman S, Judge MA, Hart PH (2010) Immune-modifying properties of topical vitamin D: Focus on dendritic cells and T cells. *J Steroid Biochem Mol Biol* 121(1-2):247–249. doi: 10.1016/j.jsbmb.2010.02.034
57. Richmond JM, Masterjohn E, Chu R, Tedstone J, Youd ME, Harris JE (2017) CXCR3 depleting antibodies prevent and reverse vitiligo in mice. *J Invest Dermatol* 137(4):982–985. doi: 10.1016/j.jid.2016.10.048
58. Richmond JM, Strassner JP, Zapata L Jr., Garg M, Riding RL, Refat MA, et al (2018) Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo. *Sci Transl Med* 10(450):eaam7710. doi: 10.1126/scitranslmed.aam7710